



NEWS RELEASE

CRINETICS PHARMACEUTICALS TO PARTICIPATE IN SVB LEERINK GLOBAL HEALTHCARE CONFERENCE

2022-02-09

SAN DIEGO – February 9, 2022 – **Crinetics Pharmaceuticals, Inc.** (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that company management will participate in a fireside chat at the annual SVB Leerink Global Healthcare Conference, which is being held in a virtual format February 14-18, 2022.

Details of the presentation are as follows:

Date: Wednesday, February 16, 2022
Time: 1:00 p.m. Eastern Time
Webcast Link: <https://wsw.com/webcast/svbleerink67/crnx/2679350>

In addition, the live and archived presentation will be accessible on the **Events & Presentations page** in the Investors section on the Company's website.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate, paltusotine, is an investigational, oral, selective nonpeptide somatostatin receptor type 2 biased agonist for the treatment of acromegaly, an orphan disease affecting more than 26,000 people in the United

States. A Phase 3 clinical program in acromegaly with paltusotine is underway. Crinetics also plans to advance paltusotine into a Phase 2 trial for the treatment of **carcinoid syndrome associated with neuroendocrine tumors**. The company is also developing **CRN04777**, an investigational, oral, nonpeptide somatostatin receptor type 5 (SST5) agonist for congenital hyperinsulinism, as well as **CRN04894**, an investigational, oral, nonpeptide ACTH antagonist for the treatment of congenital adrenal hyperplasia, Cushing's disease and other diseases of excess ACTH. All of the company's drug candidates are new chemical entities resulting from in-house drug discovery efforts and are wholly owned by the company.

Contact:

Marc Wilson

Chief Financial Officer

IR@crinetics.com

(858) 450-6464

Investors / Media:

Corey Davis

LifeSci Advisors

cdavis@lifesciadvisors.com

(212)-915-2577

Aline Sherwood

Scienta Communications

asherwood@scientapr.com

(312) 238-8957

Source: Crinetics Pharmaceuticals, Inc.